Relationships between serum adiponectin, leptin concentrations and bone mineral density, and bone biochemical markers in Chinese women.
BACKGROUND
Adiponectin and leptin, as the main circulating peptides secreted by adipose tissue, are potential contributors to bone metabolism. However, their association with bone mineral density (BMD) is unknown. We investigated whether these serum adipocytokines concentrations are associated with BMD and bone turnover markers.


METHODS
Serum adiponectin, leptin concentrations, bone turnover biochemical markers, and BMD were determined in 265 premenopausal and 336 postmenopausal Chinese women.


RESULTS
In postmenopausal Chinese women, the multiple linear stepwise regression analysis showed that year since menopause, lean mass, estradiol, and adiponectin, but not fat mass, leptin, were independent predictors of BMD in postmenopausal Chinese women. However, in premenopausal Chinese women, adiponectin was not the predictor of BMD. The significant positive correlations between adiponectin and bone-specific alkaline phosphatase (BAP), bone cross-linked N-telopeptides of type I collagen (NTX) were found only in postmenopausal women. Serum BAP, and NTX, but not adiponectin, decreased in response to alendronate therapy.


CONCLUSIONS
Adiponectin was an independent predictor of BMD, and positively correlated with bone turnover biochemical markers in postmenopausal Chinese women, but not premenopausal women. It suggested that adiponectin may exert a negative effect on bone mass by promoting excessive bone resorption associated with bone loss. However, these effects may be mediated by menopausal status.
Wu
Nan
N
Institute of Endocrinology and Metabolism, Second Xiangya Hospital of Central South University, 139# Middle Renmin Road, Changsha, Hunan 410011, PR China. [corrected]
Wang
Qing-Ping
QP
Li
Hui
H
Wu
Xian-Ping
XP
Sun
Zhen-Qiu
ZQ
Luo
Xiang-Hang
XH
D052242:Adiponectin / Q000097:blood; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D019386:Alendronate / Q000494:pharmacology / Q000627:therapeutic use; D000469:Alkaline Phosphatase / Q000097:blood; D015415:Biomarkers / Q000097:blood; D001769:Blood / Q000187:drug effects; D001823:Body Composition; D015992:Body Mass Index; D015519:Bone Density; D016723:Bone Remodeling / Q000187:drug effects; D001842:Bone and Bones / Q000378:metabolism*; D002681:China; D024042:Collagen Type I / Q000097:blood; D004311:Double-Blind Method; D004958:Estradiol / Q000097:blood; D005260:Female; D006801:Humans; D020738:Leptin / Q000097:blood*; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy; D010455:Peptides / Q000097:blood; D017698:Postmenopause / Q000097:blood / Q000378:metabolism; D017697:Premenopause / Q000097:blood / Q000378:metabolism; D016896:Treatment Outcome; D055815:Young Adult
C499918:ADIPOQ protein, human; D052242:Adiponectin; D015415:Biomarkers; D024042:Collagen Type I; D020738:Leptin; D010455:Peptides; C052929:collagen type I trimeric cross-linked peptide; D004958:Estradiol; C548267:ALPL protein, human; D000469:Alkaline Phosphatase; D019386:Alendronate